This is a deeply dilutive offering from a micro-cap with declining revenue and a history of repeated capital raises. The zero-price exercise warrants create a massive overhang of up to 63M additional shares that can be dumped into the market with no cash benefit to the company. Expect significant downward pressure on the stock price as the market prices in the dilution. Monitor for immediate selling pressure upon closing (expected July 24, 2026) and watch for any subsequent warrant exercises that would further flood the float. The cross-filing actuarial verdicts confirm this pattern historically amplifies negative returns — avoid the long side.
Price Chart
Executive Summary
China SXT Pharmaceuticals filed a 424B5 prospectus supplement for a $9M registered direct offering of 4.5M units at $2.00/unit, each consisting of one Class A ordinary share and one warrant to purchase one Class A ordinary share. The warrants have a $3.20 exercise price and a zero-price exercise feature that could result in the issuance of up to 63M additional shares with no cash proceeds to the company, massively diluting existing shareholders from 38.2M shares outstanding to potentially 105.7M shares. This is the 6th offering filing in the last 24 months for a $13M market cap company with declining revenue, and the cross-filing actuarial verdicts confirm this is an amplifier pattern — the combination of this offering with the company's prior shelf, press, and restructuring context historically amplifies negative returns.
Key Facts
- Offering of up to 4,500,000 units at $2.00/unit for aggregate gross proceeds of $9,000,000.
- Each unit consists of one Class A ordinary share and one warrant to purchase one Class A ordinary share.
- Warrants have a $3.20 exercise price and a zero-price exercise feature that could issue up to 63,000,000 additional shares with no cash proceeds.
- Pro forma as-adjusted share count would be 105,718,077 Class A ordinary shares, up from 38,218,077 pre-offering — a 176% increase in share count.
- Net proceeds to the company estimated at approximately $8.28 million after fees and expenses.
- Pro forma as-adjusted net tangible book value per share drops from $31.00 to $0.40 per share.
- Existing shareholders experience an immediate dilution of $0.49 per share; new investors experience $1.60 per share dilution.
- This is the 6th offering/registration filing by SXTC in the last 24 months.
- Revenue declined from $1,928,497 (FY2024) to $1,740,907 (FY2025), a 10% decrease.
- Company has an accumulated deficit of $34,220,402 as of March 31, 2026.
Financial Impact
Massive dilution: share count increases ~176% from 38.2M to 105.7M shares. Net tangible book value per share collapses from $31.00 to $0.40. Gross proceeds of $9M with net ~$8.28M, but warrants are unlikely to generate additional cash due to zero-price exercise feature.
Risk Factors
- Extreme dilution of ~176% in share count from warrant exercise potential.
- Zero-price exercise warrants provide no cash to the company but create massive sellable share overhang.
- Declining revenue trend (10% YoY decline) with no sign of turnaround.
- Repeated capital raises (6 offerings in 24 months) signal structural cash burn.
- VIE structure and China regulatory risks add geopolitical uncertainty.
- Nasdaq minimum bid price compliance risk if stock falls below $1.00.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (SXTC) — Batch item 1 | 0001213900-26-081135 |
| Document: 0001213900-26-081135-index-headers.html | 0001213900-26-081135 |
| Document: 0001213900-26-081135-index.html | 0001213900-26-081135 |
| Document: 0001213900-26-081135.txt | 0001213900-26-081135 |
| 424B5 Filing (SXTC) — Batch item 5 | 0001213900-26-081135 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.0480 | awaiting T+5 | — | — |
Oct 15, 2026 11d ago | SC 13G | $0.0650 $0.0410 | ▼ −36.92% | ▼ −36.49% | — |
Oct 9, 2026 17d ago | 6-K | $0.1020 $0.1112 | ▼ −9.02% | ▼ −10.51% | — |
Oct 9, 2026 17d ago | 424B5 | $0.1487 $0.0650 | ▲ +56.29% | ▲ +54.32% | — |
Oct 8, 2026 18d ago | 6-K | $0.3435 $0.0688 | ▲ +79.97% | ▲ +79.69% | — |
Oct 8, 2026 18d ago | 6-K | $0.3435 $0.0688 | ▲ +79.97% | ▲ +79.69% | — |
Sep 17, 2026 5w ago | EFFECT | $2.44 $2.55 | ▼ −4.72% | ▼ −4.12% | — |
Aug 28, 2026 8w ago | 6-K | $2.56 $2.24 | ▲ +12.50% | ▲ +12.36% | — |
Jul 24, 2026 13w ago | 424B5 | $0.0638 $0.0618 | ▲ +3.13% | ▲ +4.23% | — |
Jun 1, 2026 21w ago | 424B5 | $1.78 $1.56 | ▲ +12.36% | ▲ +9.39% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers